GlassScriptPhysician profile
Niloo Rivani
NPI 1104221258
$8,726.95
in general payments reported to CMS, 2019-2025
27 companies · $3,741 in 2025
The $3,741 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $2,672 · 2023: $1,333 · 2024: $866 · 2025: $3,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,939.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,471.98 | 2022 | |
| Janssen Biotech, INC. | $1,167.25 | 2022-2025 | Rybrevant, Carvykti, Erleada |
| Abbvie INC. | $735.21 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $629.53 | 2022-2025 | Fasenra, Calquence |
| Alexion Pharmaceuticals, INC. | $596.62 | 2023-2025 | Ultomiris |
| Madrigal Pharmaceuticals | $425.30 | 2024-2025 | Rezdiffra |
| Incyte Corporation | $389.98 | 2023-2025 | Monjuvi, Jakafi |
| Gilead Sciences, INC. | $370.38 | 2025 | Trodelvy, Yeztugo |
| Glaxosmithkline, LLC. | $360.46 | 2022-2023 | Bexsero, Shingrix |
| Paratek Pharmaceuticals, INC. | $249.24 | 2022-2023 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.71 | 2022-2023 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $226.53 | 2023 | Austedo Xr, Uzedy |
| Geron Corporation | $146.85 | 2025 | Rytelo |
| Bayer Healthcare Pharmaceuticals INC. | $144.87 | 2025 | |
| Syndax Pharmaceuticals, INC. | $144.01 | 2025 | Revuforj |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $134.00 | 2025 | Invega Sustenna, Invega Trinza |
| Amgen INC. | $131.08 | 2025 | Evenity |
| Acadia Pharmaceuticals INC | $125.00 | 2022 | |
| Csl Behring | $125.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2025 | Xifaxan |
| Sk Life Science, INC. | $124.96 | 2025 | Xcopri |
| Otsuka America Pharmaceutical, INC. | $123.06 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $118.41 | 2024 | Reblozyl |
| Allergan, INC. | $115.04 | 2022 | |
| Mylan Specialty L.P. | $109.39 | 2022 | |
| Alnylam Pharmaceuticals INC. | $98.78 | 2025 | Givlaari |
| Beone Medicines USA, INC. | $98.31 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niloo Rivani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.